| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Metabolite of palmitoylcarnitine
|
|---|---|
| ln Vivo |
Of the 741 patients with T2DM, 288 had CVD. Five factors were extracted from the 25 acylcarnitines and they accounted for 65.9% of the total variance. Factor 1 consisted of acetylcarnitine, butyrylcarnitine, hydroxylbutyrylcarnitine, glutarylcarnitine, hexanoylcarnitine, octanoylcarnitine, and tetradecanoyldiacylcarnitine. Factor 2 consisted of decanoylcarnitine, lauroylcarnitine, myristoylcarnitine, 3-hydroxyl-tetradecanoylcarnitine, tetradecenoylcarnitine, and 3-3-Hydroxyhexadecanoylcarnitine. After adjusting for potential confounders, increased factor 1 and 2 were associated with increased risks of CVD in T2DM (OR of factor 1: 1.45, 95% CI: 1.03–2.03; OR of factor 2: 1.23, 95% CI: 1.02–1.50) [1].
|
| Animal Protocol |
The inclusion criteria were set out as follows: (1) age ≥ 18 years; (2) diagnosed as T2DM; and (3) acylcarnitine metabolites were available: acetylcarnitine (C2), propionylcarnitine (C3), butyrylcarnitine (C4), hydroxylbutyrylcarnitine (C4-OH), succinylcarnitine (C4DC), isovalerylcarnitine (C5), 3-hydroxyisovalerylcarnitine (C5-OH), glutarylcarnitine (C5DC), tiglylcarnitine (C5:1), hexanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10), lauroylcarnitine (C12), myristoylcarnitine (C14), 3-hydroxyl-tetradecanoylcarnitine (C14-OH), tetradecanoyldiacylcarnitine (C14DC), tetradecenoylcarnitine (C14:1), palmitoylcarnitine (C16), 3-Hydroxyhexadecanoylcarnitine (C16-OH), 3-Hydroxyhexadecanoylcarnitine (C16:1-OH), octadecanoylcarnitine (C18), arachidic carnitine (C20), behenic carnitine (C22), tetracosanoic carnitine (C24), hexacosanoic carnitine (C26). The exclusion criteria were: (1) diagnosed as type 1 diabetes; (2) pregnancy. A total of 741 T2DM patients who met the inclusion and did not have the exclusion criteria were included in the analysis.[1]
|
| References |
[1]. The Association Between Acylcarnitine Metabolites and Cardiovascular Disease in Chinese Patients With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2020 May 5;11:212.
|
| Additional Infomation |
Objective: The association between acylcarnitine metabolites and cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) is unclear. This study aims to explore the association between acylcarnitine and CVD in Chinese patients with T2DM. Methods: This study was a cross-sectional study spanning from May 2015 to August 2016. Researchers retrieved medical records of 741 patients with T2DM from the main electronic database of the First Affiliated Hospital of Liaoning Medical University. CVD was defined as the presence of coronary artery disease (CAD), heart failure (HF), or stroke. The levels of 25 acylcarnitine metabolites in fasting plasma were determined by mass spectrometry. Factor analysis was used to reduce the dimensionality of the 25 acylcarnitine metabolites and extract factors. Multivariate binary logistic regression analysis was used to calculate the odds ratio (OR) and 95% confidence interval (CI) of the factors extracted from the 25 acylcarnitine metabolites to cardiovascular disease (CVD). [1]
|
| Molecular Formula |
C23H45NO5
|
|---|---|
| Molecular Weight |
415.61
|
| Exact Mass |
415.33
|
| CAS # |
195207-76-2
|
| PubChem CID |
126456228
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.196
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
29
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCC(O)CC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O
|
| InChi Key |
XKAZIAFZAQAHHG-BPGUCPLFSA-N
|
| InChi Code |
InChI=1S/C23H45NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-20(25)17-23(28)29-21(18-22(26)27)19-24(2,3)4/h20-21,25H,5-19H2,1-4H3/t20?,21-/m1/s1
|
| Chemical Name |
(3R)-3-(3-hydroxyhexadecanoyloxy)-4-(trimethylazaniumyl)butanoate
|
| Synonyms |
3-Hydroxyhexadecanoylcarnitine; 3-hydroxypalmitoylcarnitine; 195207-76-2; 3-Hydroxyhexadecanoylcarnitine Inner Salt (Mixture of Diastereomers); (3R)-3-(3-hydroxyhexadecanoyloxy)-4-(trimethylazaniumyl)butanoate; 1-Propanaminium, 3-carboxy-2-[(3-hydroxy-1-oxohexadecyl)oxy]-N,N,N-trimethyl-, inner salt, (2R)-; 1-Propanaminium, 3-carboxy-2-[(3-hydroxy-1-oxohexadecyl)oxy]-N,N,N-trimethyl-, inner salt, [1(R)]-; 3-Hydroxyhexadecanoylcarnitine; 3-Hydroxypalmitoylcarnitine; 3-Hydroxyhexadecanoyl L-carnitine; 3-Hydroxypalmitoyl L-carnitine; b-Hydroxypalmitoylcarnitine; b-Hydroxyhexadecanoylcarnitine;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4061 mL | 12.0305 mL | 24.0610 mL | |
| 5 mM | 0.4812 mL | 2.4061 mL | 4.8122 mL | |
| 10 mM | 0.2406 mL | 1.2031 mL | 2.4061 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
